In July 2018,<unk>  was approved in the United States for relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation. In May 2019,<unk>  was approved in the United States for newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy. In August 2021, the FDA approved<unk>  for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Ivosidenib
Enasidenib
Dabrafenib
Selpercatinib
Brigatinib
Tucatinib
Fostamatinib
Lorlatinib